Another line of evidence connecting ketones to improved cardiovascular disease is the observation that sodium-glucose co-transporter 2 (SGLT2) inhibitor drugs reduce hospitalizations and mortality in patients with diabetes [232, 233], and heart failure patients without diabetes [234]. This evidence concerns the gene SLC5A2 and diabetes mellitus.